Hairy cell leukemia:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Philadelphia [u.a.]
Saunders
2006
|
| Schriftenreihe: | Hematology, oncology clinics of North America
20,5 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XI S., S. 1011 - 1169 Ill., graph. Darst. |
| ISBN: | 1416039066 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV021806909 | ||
| 003 | DE-604 | ||
| 005 | 20061120 | ||
| 007 | t | ||
| 008 | 061113s2006 ad|| |||| 00||| eng d | ||
| 020 | |a 1416039066 |9 1-4160-3906-6 | ||
| 035 | |a (OCoLC)75482864 | ||
| 035 | |a (DE-599)BVBBV021806909 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 |a DE-19 | ||
| 082 | 0 | |a 616.99/419 |2 22 | |
| 084 | |a YC 1700 |0 (DE-625)153192: |2 rvk | ||
| 084 | |a YC 2400 |0 (DE-625)153201:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Hairy cell leukemia |c guest ed. Alan Saven |
| 264 | 1 | |a Philadelphia [u.a.] |b Saunders |c 2006 | |
| 300 | |a XI S., S. 1011 - 1169 |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Hematology, oncology clinics of North America |v 20,5 | |
| 650 | 4 | |a Leukemia, Hairy Cell | |
| 650 | 4 | |a Leukemia, Hairy cell | |
| 650 | 0 | 7 | |a Sichelzellenanämie |0 (DE-588)4181157-4 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Sichelzellenanämie |0 (DE-588)4181157-4 |D s |
| 689 | 0 | |C b |5 DE-604 | |
| 700 | 1 | |a Saven, Alan |e Sonstige |4 oth | |
| 830 | 0 | |a Hematology, oncology clinics of North America |v 20,5 |w (DE-604)BV000625446 |9 20,5 | |
| 856 | 4 | 2 | |m Digitalisierung UB Regensburg |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015019265&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-015019265 | ||
Datensatz im Suchindex
| _version_ | 1804135725479755776 |
|---|---|
| adam_text | Hairy Cell Leukemia
CONTENTS
Preface
Alan
The Pathophysiology of the Hairy Cell
J.C. Cawley
In the twenty-first century, gene microarray analysis has confirmed that
hairy cells (HCs) are activated late
to chronic lymphocytic leukemia and normal memory
any other B-cell type examined. This approach also revealed the specific
expression of several genes that might have pathophysiologic and
diagnostic importance. Also, cell-signaling studies have defined the
mechanistic basis of several of the distinctive features of HCs; however,
such studies have not identified the oncogenic source of these intrinsic
signals. Therefore, identification of the oncogenic events that are res¬
ponsible for the distinctive phenotype of HCs is the biggest remaining
challenge in the disease.
Hairy Cell Leukemia: Diagnostic Pathology
Robert W.
The hematopathology of hairy cell leukemia (HCL) is discussed. HCL
has distinctive morphologic features that permitted accurate diagnosis
even before the development of ancillary methods. In the last several
decades flow cytometry and immunohistochemistry have replaced
traditional cytochemical and
a morphologic impression of HCL. The characteristic morphologic and
ancillary findings and the role that they play in discriminating HCL
from other neoplasms are described. With the advent of extremely
effective chemotherapy for HCL, the evaluation of posttherapy bone
marrow biopsies for evidence of residual disease has increased in
importance and is discussed. Lastly, the pathology of the variant form
of HCL and the relationship of this entity to typical HCL and splenic
marginal zone lymphoma are presented.
Immunophenotyping and Differential Diagnosis
of Hairy Cell Leukemia
Estella
The cells of hairy cell leukemia and its variant form have a distinct
immunophenotype that seems to correspond to that of a mature
activated memory
CONTENTS
histology and membrane marker expression, such as the selected
immunoglobulin heavy-chain expression and the reactivity with certain
B-cell activation markers, there are differences in their clinical course,
morphology, and imrmmophenotype. Immunophenotyping is an
essential tool for the diagnosis of these two disorders, for monitoring
and assessing response to therapy, and for distinguishing them from
other B-cell malignancies.
Clinical Presentations and Complications of Hairy Cell
Leukemia
Mark A. Hoffman
Hairy cell leukemia typically presents in middle-aged men and is
characterized by splenomegaly and cytopenias. Hepatomegaly may be
present, but usually is not a salient feature. Peripheral adenopathy is
uncommon. Other organ manifestations occur but are unusual. Patients
are now presenting with a less tumor burden because of earlier diagnosis.
Leukocytosis/lymphocytosis should suggest hairy cell leukemia variant.
Infectious complications, which were common in the past and the major
cause of death, have become rare in the era of
Whether there is a true increased risk for second malignancies remains
controversial.
Splenectomy,
Interest in Hairy Cell Leukemia
Thomas M. Habermann
Hair) cell leukemia (HCL) is an uncommon leukemia. After
lymphoma, HCL has been a model for incorporating and understanding
the clinical interventions of surgery, chemotherapy, biologic response
modifiers,
Advances in treatment, all of which were empiric at the time, preceded
advancements in understanding the biology of the disease. The history
of therapeutic intervention has been characterized by empiric inter¬
ventions without scientific bench research applied to a disease that did
not have good outcomes or therapeutic interventions. Such approaches
have changed the natural history of this disease and opened doors for
other diseases. Over time, the definitions of response evolved into
modern response definitions. This article focuses on treatments of
historical interest, observation, splenectomy, and the
Purine
Mechanisms of Action, and Pharmacokinetics in Hairy
Cell Leukemia
Gunnar Juliusson
Cladribine is effective therapy for hairy cell leukemia, and there are
several ways to achieve the adequate concentrations of the active
VI
CONTENTS
metabolites in relevant cells, without the need for long-term continuous
infusions. This simplifies therapy, although careful control of patients is
required during and after treatment in most instances because of the
significant activity of the drug on leukemia cells of various types and on
lymphoid cells and normal stem cells.
Pentostatin: Impact on Outcome in Hairy Cell
Leukemia
Michael R.
Major advances in the management of patients who have hairy cell
leukemia have been made following the use of
Pentostatin and cladribine are equally effective, and have impressive
long-term effectiveness. The gradual, but relentless, improvement in the
peripheral blood counts enables the outpatient management with
pentostatin in most patients. Gladribine affords the convenience of
a single course of administration. A direct comparative study with these
two agents is unlikely to yield dramatic differences in improvement.
Patients still relapse, and the overall survival curves have not reached
a plateau, which indicates that cure has not been secured. Future studies
should be directed to optimizing the therapy for minimal residual disease
as well as clearer definition of supportive care.
Cladribine in Hairy Cell Leukemia
Rajesh Belani and Alan
Cladribine is
to the treatment of indolent lymphoid malignancies, especially hairy cell
leukemia (HCL). It induces apoptosis of hairy cells, and, thereby, induces
prolonged complete remissions in most patients. This article reviews the
history, rationale, chemical structure, mechanism of action, clinical
activity, and
relapse after cladribine, also are discussed.
Monoclonal Antibody Therapy for Hairy Cell
Leukemia
Deborah A. Thomas, Farhad Ravandi, and Hagop Kantarjian
The use of monoclonal antibody (MoAb) therapy for the treatment of
hairy cell leukemia (HCL) offers great promise and potential for
improving progression-free survival. Rituximab has activity in pre¬
viously treated HCL and the ability to eradicate minimal residual
disease after 2-chlorodeoxyadenosine given as frontline therapy.
Alemtuzumab, epratozumab. and other candidate MoAb s should be
studied in HCL. Appropriate
antigen modulation, and assessments of soluble antigen levels should be
considered with future clinical trials of MoAb s in HCL to optimize
therapeutic strategies.
vii
CONTENTS
Immunotoxins in
Cell Leukemia
Robert J. Kreitman and
An increasing number of patients who have hairy cell leukemia (HCL)
have persistent disease that requires treatment, despite
splenectomy,
been treated successfully with immunotoxins. An immunotoxin contains
a protein toxin connected to a cell-binding ligand, such as an antibody.
An immunotoxin recognizes the target cell, internalizes, and the toxin
translocates to the cytosol where it inhibits protein synthesis enzymat-
ically. Immunotoxins that show activity in HCL contain truncated
Pseudommas exotoxin fused to the Fv fragments of anti-CD25 or anti-
CD22 monoclonal antibodies. Both agents, termed LMB-2 and BL22,
respectively, have been tested in patients who have HCL after failure of
purine
in most patients.
Hairy Cell Leukemia: Towards a Curative Strategy
Adi Gidron and Martin S. Tallman
Although not all patients who have hairy cell leukemia (HCL) require
therapy at diagnosis, most eventually will need treatment. Historically,
splenectomy and interferon-cx resulted in
however, responses tend to be short, as is survival. The introduction
of
who have HCL. It is now considered standard of care to use
analog as first-line therapy. This approach results in a high complete
remission rate and prolonged disease-free survival. Despite the excellent
results with
detected by sensitive techniques; 3O°/o to
relapse and most require further therapy. For patients who have
relapsed or refractory disease, monoclonal antibody-based therapies
are emerging options.
Index
VIII
|
| adam_txt |
Hairy Cell Leukemia
CONTENTS
Preface
Alan
The Pathophysiology of the Hairy Cell
J.C. Cawley
In the twenty-first century, gene microarray analysis has confirmed that
hairy cells (HCs) are activated late
to chronic lymphocytic leukemia and normal memory
any other B-cell type examined. This approach also revealed the specific
expression of several genes that might have pathophysiologic and
diagnostic importance. Also, cell-signaling studies have defined the
mechanistic basis of several of the distinctive features of HCs; however,
such studies have not identified the oncogenic source of these intrinsic
signals. Therefore, identification of the oncogenic events that are res¬
ponsible for the distinctive phenotype of HCs is the biggest remaining
challenge in the disease.
Hairy Cell Leukemia: Diagnostic Pathology
Robert W.
The hematopathology of hairy cell leukemia (HCL) is discussed. HCL
has distinctive morphologic features that permitted accurate diagnosis
even before the development of ancillary methods. In the last several
decades flow cytometry and immunohistochemistry have replaced
traditional cytochemical and
a morphologic impression of HCL. The characteristic morphologic and
ancillary findings and the role that they play in discriminating HCL
from other neoplasms are described. With the advent of extremely
effective chemotherapy for HCL, the evaluation of posttherapy bone
marrow biopsies for evidence of residual disease has increased in
importance and is discussed. Lastly, the pathology of the variant form
of HCL and the relationship of this entity to typical HCL and splenic
marginal zone lymphoma are presented.
Immunophenotyping and Differential Diagnosis
of Hairy Cell Leukemia
Estella
The cells of hairy cell leukemia and its variant form have a distinct
immunophenotype that seems to correspond to that of a mature
activated memory
CONTENTS
histology and membrane marker expression, such as the selected
immunoglobulin heavy-chain expression and the reactivity with certain
B-cell activation markers, there are differences in their clinical course,
morphology, and imrmmophenotype. Immunophenotyping is an
essential tool for the diagnosis of these two disorders, for monitoring
and assessing response to therapy, and for distinguishing them from
other B-cell malignancies.
Clinical Presentations and Complications of Hairy Cell
Leukemia
Mark A. Hoffman
Hairy cell leukemia typically presents in middle-aged men and is
characterized by splenomegaly and cytopenias. Hepatomegaly may be
present, but usually is not a salient feature. Peripheral adenopathy is
uncommon. Other organ manifestations occur but are unusual. Patients
are now presenting with a less tumor burden because of earlier diagnosis.
Leukocytosis/lymphocytosis should suggest hairy cell leukemia variant.
Infectious complications, which were common in the past and the major
cause of death, have become rare in the era of
Whether there is a true increased risk for second malignancies remains
controversial.
Splenectomy,
Interest in Hairy Cell Leukemia
Thomas M. Habermann
Hair)' cell leukemia (HCL) is an uncommon leukemia. After
lymphoma, HCL has been a model for incorporating and understanding
the clinical interventions of surgery, chemotherapy, biologic response
modifiers,
Advances in treatment, all of which were empiric at the time, preceded
advancements in understanding the biology of the disease. The history
of therapeutic intervention has been characterized by empiric inter¬
ventions without scientific bench research applied to a disease that did
not have good outcomes or therapeutic interventions. Such approaches
have changed the natural history of this disease and opened doors for
other diseases. Over time, the definitions of response evolved into
modern response definitions. This article focuses on treatments of
historical interest, observation, splenectomy, and the
Purine
Mechanisms of Action, and Pharmacokinetics in Hairy
Cell Leukemia
Gunnar Juliusson
Cladribine is effective therapy for hairy cell leukemia, and there are
several ways to achieve the adequate concentrations of the active
VI
CONTENTS
metabolites in relevant cells, without the need for long-term continuous
infusions. This simplifies therapy, although careful control of patients is
required during and after treatment in most instances because of the
significant activity of the drug on leukemia cells of various types and on
lymphoid cells and normal stem cells.
Pentostatin: Impact on Outcome in Hairy Cell
Leukemia
Michael R.
Major advances in the management of patients who have hairy cell
leukemia have been made following the use of
Pentostatin and cladribine are equally effective, and have impressive
long-term effectiveness. The gradual, but relentless, improvement in the
peripheral blood counts enables the outpatient management with
pentostatin in most patients. Gladribine affords the convenience of
a single course of administration. A direct comparative study with these
two agents is unlikely to yield dramatic differences in improvement.
Patients still relapse, and the overall survival curves have not reached
a plateau, which indicates that cure has not been secured. Future studies
should be directed to optimizing the therapy for minimal residual disease
as well as clearer definition of supportive care.
Cladribine in Hairy Cell Leukemia
Rajesh Belani and Alan
Cladribine is
to the treatment of indolent lymphoid malignancies, especially hairy cell
leukemia (HCL). It induces apoptosis of hairy cells, and, thereby, induces
prolonged complete remissions in most patients. This article reviews the
history, rationale, chemical structure, mechanism of action, clinical
activity, and
relapse after cladribine, also are discussed.
Monoclonal Antibody Therapy for Hairy Cell
Leukemia
Deborah A. Thomas, Farhad Ravandi, and Hagop Kantarjian
The use of monoclonal antibody (MoAb) therapy for the treatment of
hairy cell leukemia (HCL) offers great promise and potential for
improving progression-free survival. Rituximab has activity in pre¬
viously treated HCL and the ability to eradicate minimal residual
disease after 2-chlorodeoxyadenosine given as frontline therapy.
Alemtuzumab, epratozumab. and other candidate MoAb"s should be
studied in HCL. Appropriate
antigen modulation, and assessments of soluble antigen levels should be
considered with future clinical trials of MoAb's in HCL to optimize
therapeutic strategies.
vii
CONTENTS
Immunotoxins in
Cell Leukemia
Robert J. Kreitman and
An increasing number of patients who have hairy cell leukemia (HCL)
have persistent disease that requires treatment, despite
splenectomy,
been treated successfully with immunotoxins. An immunotoxin contains
a protein toxin connected to a cell-binding ligand, such as an antibody.
An immunotoxin recognizes the target cell, internalizes, and the toxin
translocates to the cytosol where it inhibits protein synthesis enzymat-
ically. Immunotoxins that show activity in HCL contain truncated
Pseudommas exotoxin fused to the Fv fragments of anti-CD25 or anti-
CD22 monoclonal antibodies. Both agents, termed LMB-2 and BL22,
respectively, have been tested in patients who have HCL after failure of
purine
in most patients.
Hairy Cell Leukemia: Towards a Curative Strategy
Adi Gidron and Martin S. Tallman
Although not all patients who have hairy cell leukemia (HCL) require
therapy at diagnosis, most eventually will need treatment. Historically,
splenectomy and interferon-cx resulted in
however, responses tend to be short, as is survival. The introduction
of
who have HCL. It is now considered standard of care to use
analog as first-line therapy. This approach results in a high complete
remission rate and prolonged disease-free survival. Despite the excellent
results with
detected by sensitive techniques; 3O°/o to
relapse and most require further therapy. For patients who have
relapsed or refractory disease, monoclonal antibody-based therapies
are emerging options.
Index
VIII |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| building | Verbundindex |
| bvnumber | BV021806909 |
| classification_rvk | YC 1700 YC 2400 |
| ctrlnum | (OCoLC)75482864 (DE-599)BVBBV021806909 |
| dewey-full | 616.99/419 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.99/419 |
| dewey-search | 616.99/419 |
| dewey-sort | 3616.99 3419 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01558nam a2200397 cb4500</leader><controlfield tag="001">BV021806909</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20061120 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">061113s2006 ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1416039066</subfield><subfield code="9">1-4160-3906-6</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)75482864</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV021806909</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-19</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.99/419</subfield><subfield code="2">22</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YC 1700</subfield><subfield code="0">(DE-625)153192:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YC 2400</subfield><subfield code="0">(DE-625)153201:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Hairy cell leukemia</subfield><subfield code="c">guest ed. Alan Saven</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Philadelphia [u.a.]</subfield><subfield code="b">Saunders</subfield><subfield code="c">2006</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XI S., S. 1011 - 1169</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Hematology, oncology clinics of North America</subfield><subfield code="v">20,5</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Leukemia, Hairy Cell</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Leukemia, Hairy cell</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Sichelzellenanämie</subfield><subfield code="0">(DE-588)4181157-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Sichelzellenanämie</subfield><subfield code="0">(DE-588)4181157-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="C">b</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Saven, Alan</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Hematology, oncology clinics of North America</subfield><subfield code="v">20,5</subfield><subfield code="w">(DE-604)BV000625446</subfield><subfield code="9">20,5</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Regensburg</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015019265&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-015019265</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV021806909 |
| illustrated | Illustrated |
| index_date | 2024-07-02T15:49:32Z |
| indexdate | 2024-07-09T20:45:04Z |
| institution | BVB |
| isbn | 1416039066 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-015019265 |
| oclc_num | 75482864 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR DE-19 DE-BY-UBM |
| owner_facet | DE-355 DE-BY-UBR DE-19 DE-BY-UBM |
| physical | XI S., S. 1011 - 1169 Ill., graph. Darst. |
| publishDate | 2006 |
| publishDateSearch | 2006 |
| publishDateSort | 2006 |
| publisher | Saunders |
| record_format | marc |
| series | Hematology, oncology clinics of North America |
| series2 | Hematology, oncology clinics of North America |
| spelling | Hairy cell leukemia guest ed. Alan Saven Philadelphia [u.a.] Saunders 2006 XI S., S. 1011 - 1169 Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Hematology, oncology clinics of North America 20,5 Leukemia, Hairy Cell Leukemia, Hairy cell Sichelzellenanämie (DE-588)4181157-4 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Sichelzellenanämie (DE-588)4181157-4 s b DE-604 Saven, Alan Sonstige oth Hematology, oncology clinics of North America 20,5 (DE-604)BV000625446 20,5 Digitalisierung UB Regensburg application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015019265&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Hairy cell leukemia Hematology, oncology clinics of North America Leukemia, Hairy Cell Leukemia, Hairy cell Sichelzellenanämie (DE-588)4181157-4 gnd |
| subject_GND | (DE-588)4181157-4 (DE-588)4143413-4 |
| title | Hairy cell leukemia |
| title_auth | Hairy cell leukemia |
| title_exact_search | Hairy cell leukemia |
| title_exact_search_txtP | Hairy cell leukemia |
| title_full | Hairy cell leukemia guest ed. Alan Saven |
| title_fullStr | Hairy cell leukemia guest ed. Alan Saven |
| title_full_unstemmed | Hairy cell leukemia guest ed. Alan Saven |
| title_short | Hairy cell leukemia |
| title_sort | hairy cell leukemia |
| topic | Leukemia, Hairy Cell Leukemia, Hairy cell Sichelzellenanämie (DE-588)4181157-4 gnd |
| topic_facet | Leukemia, Hairy Cell Leukemia, Hairy cell Sichelzellenanämie Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015019265&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000625446 |
| work_keys_str_mv | AT savenalan hairycellleukemia |